Startup launches to commercialize AI-designed personalized mRNA cancer vaccines for dogs

Paul Conyngham, an Australian tech entrepreneur, founded Gamgee to commercialize AI-designed personalized mRNA cancer vaccines for dogs. Conyngham cited a case involving his own dog, Rosie, a Staffordshire bull terrier-Shar Pei mix, whose tumors reportedly shrank after receiving a personalized mRNA vaccine designed with the help of AI tools including ChatGPT and Grok.

The company’s website and promotional materials prominently feature Rosie and other dogs, emphasizing its mission to deliver personalized cancer treatments at scale. Gamgee’s ambitions extend beyond pets to humans, positioning itself as a platform for AI-driven personalized medicine across species.

However, reporting by The Verge earlier this year questioned the scientific basis of Gamgee’s core claim. Researchers noted that the protocol Rosie followed included multiple therapies, making it impossible to attribute her improvement solely to the mRNA vaccine. The exact role of AI in the treatment process was also unclear, with experts suggesting the technology was overstated while downplaying human involvement.

Gamgee is backed by Y Combinator and states it is recruiting for its first clinical trials in Australia, with a global waitlist open for veterinary cases. The company claims a roughly 75 percent tumor reduction in its “first documented case,” though it cautions this is based on a single case and may vary. Gamgee also promises veterinarians can complete the process in less than 20 minutes, deliver a finished vaccine in around four weeks, and avoid new clinical workflows. Costs are not disclosed on the website.

Gamgee says it is collaborating with the University of Queensland and institutes at the University of New South Wales in Australia. The company encourages potential funders or study partners to reach out as it pursues broader applications in personalized medicine.